查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1950477

镰状细胞疾病基因治疗市场按治疗模式、改良技术、严重程度、支付方类别、患者年龄和分销管道划分，全球预测，2026-2032年

Gene Therapy for Sickle Cell Disease Market by Treatment Model, Modification Technology, Severity, Payer Category, Patient Age, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，镰状细胞疾病基因治疗市场规模将达到 21.5 亿美元，到 2026 年将达到 24.9 亿美元。预计到 2032 年，该市场规模将达到 52.5 亿美元，年复合成长率为 13.60%。

关键市场统计数据
基准年 2025 21.5亿美元
预计年份：2026年 24.9亿美元
预测年份 2032 52.5亿美元
复合年增长率 (%) 13.60%

镰状细胞疾病基因疗法的现代治疗格局，以及科学知识、医疗服务和政策之间的相互作用如何影响其应用。

镰状细胞疾病正处于关键的转折点，数十年的临床观察与精准基因介入在此交汇。近年来，科学进步、监管里程碑以及日益成熟的临床计画共同推动了治疗理念从症状管理转向持久的缓解疾病。在此背景下，相关人员正在重新调整工作重点，以满足持续存在的未满足需求，同时应对根治性治疗技术所特有的复杂安全性、生产和可及性挑战。

近期技术进步、监管政策明朗化以及整合医学创新如何推动镰状细胞疾病治疗从症状治疗转向持久的基因改造

镰状细胞疾病治疗格局正从渐进式的症状治疗转向具有变革意义的基因干预，这些干预措施有望重塑长期的临床预期。基因编辑精准性、载体设计和预处理方案的进步正在降低传统的疗效和安全性障碍，促使研发重点和治疗模式进行重新调整。同时，细胞生产物流的改进和分散式治疗路径的建立，正在催生新的治疗方法，这些方法在提高患者容量的同时，也能维持严格的品管。

评估2025年关税变化对基因治疗跨境采购、生产韧性和专案连续性的实际和策略影响

2025年推出的政策变化和关税调整，为包括基因治疗试剂和细胞处理设备在内的先进生物製药产品的跨境采购和供应链规划带来了新的复杂性。这些贸易措施正在影响依赖全球采购载体、试剂和特殊耗材的製造商的成本结构和物流计算。因此，各公司正在重新评估其供应链冗余和近岸外包策略，以确保专案进度和品管。

基于深度细分的指导将治疗模式、编辑平台、患者群体、疾病严重程度、支付方组成和交付管道与商业化策略联繫起来。

細項分析为疗法研发者和医疗保健系统提供了一个多维观点，帮助他们确定投资优先顺序并设计差异化的价值提案。基于治疗模式的「异基因」和「自体」二分法揭示了生产复杂性、预处理要求以及供体选择和个体化细胞处理的物流方面的差异。基于基因修饰技术，碱基编辑、CRISPR/Cas9、慢病毒载体和锌指核酸酶之间的差异会影响关于精准性、脱靶风险以及针对特定载体或编辑平台的品管需求的讨论。基于患者年龄，成人和儿童族群在预处理耐受性、长期安全性监测以及早期疗育的伦理要求方面存在不同的考虑因素。基于疾病严重程度，针对中度疾病和重症疾病的治疗方案必须平衡风险接受度和潜在临床效益，以确定合格标准和试验终点。基于支付方类型，政府、自费和私人支付方之间的动态会影响报销途径、预核准通讯协定和可负担性计画。根据通路，透过医院和专科护理中心进行交付会影响资格认证、跨专业护理的协调以及中心如何收集长期结果数据。

区域比较和基础设施现状将影响全球临床应用、报销和交付模式。

区域趋势将显着影响镰状细胞疾病基因疗法的临床和商业性轨迹，每个主要区域的监管环境、基础设施和支付方考量各不相同。在美洲，成熟的医疗卓越中心和活跃的患者权益倡导组织为早期临床应用创造了有利条件，而分散的支付方格局则需要量身定制的报销策略和多方价值提案。在欧洲、中东和非洲地区，监管和交付环境的异质性——集中的监管结构和多样化的国家支付体系——有利于适应性市场进入模式和区域性生产伙伴关係。在亚太地区，临床试验能力的快速增长、对细胞和基因疗法生产投资的不断增加以及不同程度的报销体系成熟度，都要求制定分阶段的、针对特定区域的商业化计划。

绘製领先的开发商、製造合作伙伴和服务供应商的策略行动图，这些行动将科学差异化与规模化和与支付方的合作相结合。

企业策略展现出多元化的发展路径，开发商和服务供应商正努力将科学与商业执行结合。一些领先的生物技术公司和成熟的细胞疗法生产商正采取差异化发展路径，专注于特定的基因编辑平台、载体技术或同种异体移植生产，以解决扩充性和可重复性问题。另一些公司则专注于临床项目，优先考虑儿童适应症或严重表型，因为这些领域潜在的显着临床效益能够增强其获得医保报销的必要性。

为赞助商和医疗系统领导者提供切实可行的策略步骤，以确保临床成功、营运韧性以及支付方为永续基因治疗做好准备的证据。

产业领导者应采取多管齐下的策略，平衡近期临床实施与可扩展营运和支付方证据累积的投资。首先，在研究设计中优先考虑稳健的安全性和持久性终点，并扩大註册登记参与范围，以确保收集能够解决支付方和监管机构担忧的纵向资料。同时，加强与专业治疗中心和区域生产合作伙伴的协作，并建立冗余、品质有保障的供应链，以降低跨境中断和关税相关风险。

调查方法的透明度：说明了专家访谈、临床和监管文件的综合分析以及用于得出具有实际操作意义的研究结果的三角验证证据。

我们的研究途径结合了定性和定量技术，对临床、营运和政策方面进行了严谨的分析。主要研究包括对临床研究人员、治疗中心管理人员、监管顾问和支付方代表进行结构化访谈，以了解实际运作中的限制和决策标准。二级资讯来源包括同行评审文献、clinicaltrials.gov 註册资讯、监管指导文件和行业白皮书，以阐明临床终点、安全信号和监管先例的背景。

一篇综述重点阐述了科学进步、作战准备和多方相关人员证据生成之间的相互作用，这些对于持续的治疗效果至关重要。

镰状细胞疾病基因疗法正逐步迈向技术可行性、临床前景和系统层面准备好三者融合，最终为患者带来显着获益的阶段。儘管科学创新已克服了一些历史遗留的技术障碍，但实际的成功仍取决于各方在提升生产能力、加强临床医生培训、与支付方合作以及了解长期疗效等方面的共同投入。积极应对这些营运和证据方面的迫切需求的相关人员，将找到实现持续临床影响和负责任的商业化的最直接途径。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章镰状细胞疾病基因治疗市场（依治疗模式划分）

  • 同种异体移植
  • 自体移植

第九章镰状细胞疾病基因治疗市场（依修饰技术划分）

  • 基础编辑
  • CRISPR/Cas9
  • 慢病毒载体
  • 锌指核酸酶

第十章 依严重程度分類的镰状细胞疾病基因治疗市场

  • 缓和
  • 严重

第十一章镰状细胞疾病基因治疗市场（依支付方分类）

  • 政府
  • 自费
  • 私人的

第十二章镰状细胞疾病基因治疗市场（依患者年龄划分）

  • 成人
  • 儿童

第十三章镰状细胞疾病基因治疗市场（依通路划分）

  • 医院
  • 专业治疗中心

第十四章镰状细胞疾病基因治疗市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章镰状细胞疾病基因治疗市场（依族群划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国镰状细胞疾病基因治疗市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

17. 美国：镰状细胞疾病基因治疗市场

18. 中国：镰状细胞疾病基因治疗市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agios Pharmaceuticals, Inc.
  • Beam Therapeutics, Inc.
  • Bluebird Bio, Inc.
  • Bristol-Myers Squibb Company
  • CRISPR Therapeutics AG
  • Editas Medicine, Inc.
  • EditForce, Inc.
  • Emmaus Life Sciences, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Fulcrum Therapeutics, Inc.
  • Global Blood Therapeutics, Inc.
  • Graphite Bio, Inc.
  • Homology Medicines, Inc.
  • Imara, Inc.
  • Incyte Corporation
  • Intellia Therapeutics, Inc.
  • JCR Pharmaceuticals Co., Ltd.
  • Magenta Therapeutics, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Precision BioSciences, Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi SA
  • Vertex Pharmaceuticals Incorporated
  • Vifor Pharma AG
Product Code: MRR-4F7A6D4FD88C

The Gene Therapy for Sickle Cell Disease Market was valued at USD 2.15 billion in 2025 and is projected to grow to USD 2.49 billion in 2026, with a CAGR of 13.60%, reaching USD 5.25 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.15 billion
Estimated Year [2026] USD 2.49 billion
Forecast Year [2032] USD 5.25 billion
CAGR (%) 13.60%

Framing the contemporary therapeutic landscape for sickle cell disease gene therapies and the interplay of science, care delivery, and policy influencing adoption

Sickle cell disease stands at an inflection point where decades of clinical observation intersect with precision genetic interventions. The last several years have produced a convergence of scientific advances, regulatory milestones, and clinical program maturation that together are transforming the therapeutic conversation from symptom management to durable disease modification. Against this backdrop, stakeholders across biopharma, clinical practice, and payer communities are recalibrating priorities to address long-standing unmet needs while navigating the complex safety, manufacturing, and access challenges unique to curative-intent technologies.

This report opens with a concise orientation to the biological rationale for gene-based approaches and the contemporary clinical evidence that supports their use in severe phenotypes. It contextualizes the evolution of therapy from autologous hematopoietic stem cell transplants to engineered ex vivo and in vivo modalities, and it highlights how regulatory frameworks and early reimbursement dialogues are influencing trial design and commercial planning. The introduction also outlines the critical intersections between patient advocacy, specialized treatment centers, and academic research networks that will shape adoption pathways over the coming years.

By establishing this foundation, readers will be better equipped to interpret subsequent sections that analyze technological differentiation, payer engagement, regional delivery infrastructure, and company strategies. The goal is to present an integrated starting point that informs clinical decision-making, strategic partnerships, and investment priorities without presupposing a single adoption trajectory.

How recent technical advances, regulatory clarity, and integrated care innovations are shifting sickle cell treatment from symptomatic care toward durable genetic transformation

The landscape for treating sickle cell disease has shifted from incremental symptomatic care toward potentially transformative genetic interventions that reframe long-term clinical expectations. Advances in editing accuracy, vector design, and conditioning regimens have reduced historical barriers to efficacy and safety, prompting a recalibration of R&D priorities and care models. Concurrently, improvements in cell-manufacturing logistics and decentralized care pathways are enabling new approaches to patient throughput while preserving stringent quality controls.

Scientific progress has been complemented by regulatory clarity in key regions, which has encouraged more robust comparative trial designs and earlier engagement between developers and payers. This regulatory momentum, in turn, has accelerated collaborations between specialized treatment centers and industry partners to pilot end-to-end programs that integrate patient identification, enrollment, and long-term follow-up. As a result, the ecosystem is shifting from isolated clinical demonstrations to coordinated networks that can support broader, systematic adoption.

Clinically, the focus is gravitating toward durable clinical benefit, patient-centered outcomes, and safety profiles that are acceptable in both adult and pediatric populations. These priorities are driving cross-disciplinary investments in biomarker development, registry expansion, and health economics initiatives to demonstrate value. Taken together, these transformative shifts signal a maturing field where scientific promise is increasingly matched by pragmatic efforts to establish sustainable care and reimbursement models.

Assessing the practical operational and strategic consequences of 2025 tariff changes on cross-border sourcing, manufacturing resilience, and program continuity for gene therapies

Policy changes and tariff adjustments introduced in 2025 have added a new layer of complexity to cross-border procurement and supply chain planning for advanced biologics, including gene therapy reagents and cell-processing equipment. These trade measures have affected the cost structure and logistical calculus for manufacturers that rely on globalized sourcing of vectors, reagents, and specialized disposables. As a result, companies are reassessing supply-chain redundancy and nearshoring strategies to protect program timelines and quality oversight.

In response, many program leaders are intensifying supplier qualification processes and expanding dual-sourcing agreements to mitigate disruption risks. They are also accelerating investments in regional manufacturing capabilities and modular production platforms that can be deployed closer to clinical sites. This reorientation supports shorter lead times and reduces exposure to tariff volatility, while preserving sterile-chain integrity and regulatory compliance.

Operationally, clinicians and treatment centers are collaborating more closely with manufacturers to align scheduling windows and manage inventory buffers tied to domestic customs workflows. At the same time, payers and procurement officers are scrutinizing total cost of care and supply risk, prompting earlier price and access discussions. The net effect is a pragmatic repositioning of commercial and clinical strategies to maintain program resilience in the face of trade-related headwinds.

Deep segmentation-driven guidance linking treatment model, editing platform, patient demographics, severity profiles, payer mix, and delivery channel to commercialization strategy

Segmentation analysis provides a multidimensional lens through which therapeutic developers and health systems can prioritize investments and design differentiated value propositions. Based on Treatment Model, the dichotomy between Allogeneic and Autologous approaches informs manufacturing complexity, conditioning requirements, and logistics for donor selection versus individualized cell handling. Based on Modification Technology, distinctions among Base Editing, CRISPR/Cas9, Lentiviral Vector, and Zinc Finger Nuclease influence the narrative around precision, off-target risk, and the need for vector or editing platform-specific quality controls. Based on Patient Age, considerations differ for Adult and Pediatric populations with respect to conditioning tolerance, long-term safety surveillance, and ethical imperatives for early intervention. Based on Severity, approaches tailored to Moderate versus Severe disease must balance risk tolerance against potential clinical benefit, determining eligibility criteria and trial endpoints. Based on Payer Category, the dynamics among Government, Out Of Pocket, and Private payers shape reimbursement pathways, prior authorization protocols, and affordability programs. Based on Distribution Channel, delivery through Hospital versus Specialty Treatment Center has implications for credentialing, multidisciplinary care coordination, and how centers capture long-term outcome data.

Integrating these segmentation axes reveals nuanced opportunities for therapeutic differentiation. For example, a platform with a favorable safety profile that targets pediatric severe phenotypes may prioritize specialty treatment centers for early adoption and cultivate government and private payer dialogues focused on long-term outcome data. Conversely, treatments that rely on established lentiviral processes may lean into hospital networks with existing hematopoietic stem cell transplant infrastructure to scale capacity. Strategic plans that explicitly map technology attributes to patient demographics, disease severity, payer mix, and delivery channels will be better positioned to anticipate operational bottlenecks and accelerate patient access.

Comparative regional dynamics and infrastructure realities shaping clinical adoption, reimbursement engagement, and delivery models across global geographies

Regional dynamics materially influence the clinical and commercial trajectory of gene therapies for sickle cell disease, with distinct regulatory, infrastructural, and payer considerations across major geographies. In the Americas, established centers of excellence and active patient advocacy groups create fertile ground for early clinical adoption, while fragmented payer landscapes necessitate tailored reimbursement strategies and multi-stakeholder value narratives. Europe, Middle East & Africa presents a heterogeneous regulatory and delivery environment where centralized regulatory mechanisms coexist with diverse national payer systems, encouraging adaptive market-entry models and regional manufacturing partnerships. Asia-Pacific features a mix of rapidly expanding clinical trial capacity, growing investments in cell and gene therapy manufacturing, and variable reimbursement maturity that make phased, region-specific commercialization plans essential.

In all regions, the availability of specialized treatment centers, the density of experienced transplant teams, and the maturity of post-therapy registries determine practical access pathways. Additionally, regional differences in newborn screening programs, genetic counseling infrastructure, and public health priorities affect patient identification and recruitment strategies. Cross-border collaborations, technology transfer agreements, and local training programs are proving effective in addressing workforce constraints and accelerating the safe rollout of complex therapies.

Understanding these regional nuances allows sponsors and health system planners to align clinical development with scalable delivery models and payer engagement strategies that reflect local regulatory expectations and infrastructure realities.

Mapping the strategic behaviors of leading developers, manufacturing partners, and service providers that combine scientific differentiation with operational scale and payer engagement

Company strategies demonstrate a spectrum of approaches as developers and service providers align scientific capabilities with operational execution. Several leading biotechnology companies and established cell therapy manufacturers are pursuing differentiated pathways that emphasize specific editing platforms, vector expertise, or allogeneic manufacturing to address scalability and repeatability. Others are concentrating on clinical programs that prioritize pediatric indications or severe phenotypes where the potential for pronounced clinical benefit can strengthen reimbursement narratives.

Partnership models are increasingly common, pairing platform owners with contract development and manufacturing organizations to accelerate capacity expansion and reduce time-to-clinic risk. In parallel, collaborations between industry stakeholders and specialized treatment centers help operationalize care pathways, standardize safety monitoring, and aggregate long-term outcomes. Investors and strategic partners are also supporting companies that demonstrate robust quality systems, scalable supply chains, and credible plans for long-term patient follow-up.

Service providers that offer end-to-end logistics, cryopreservation, vector manufacturing, or long-term registry management are becoming essential components of the ecosystem. Their role is particularly pronounced for sponsors seeking to decouple clinical execution from in-house manufacturing complexities while preserving regulatory compliance. The evolving competitive landscape rewards entities that can combine scientific differentiation with demonstrated operational rigor and constructive payer engagement.

Actionable strategic moves for sponsors and health system leaders to secure clinical success, resilient operations, and payer-aligned evidence for durable gene therapies

Industry leaders should adopt a multitrack strategy that balances near-term clinical execution with investments in scalable operations and payer-facing evidence generation. First, prioritize robust safety and durability endpoints in trial design and expand registry participation to ensure longitudinal data capture that addresses payer and regulatory concerns. Simultaneously, cultivate partnerships with specialized treatment centers and regional manufacturing partners to create redundant, quality-assured supply chains that mitigate cross-border disruptions and tariff-related risks.

Second, tailor value communication to specific payer audiences by producing clear, mechanism-linked outcomes evidence and patient-centered metrics. Engage government, private, and out-of-pocket payer representatives early to co-design reimbursement pathways and outcomes-based contracting pilots where feasible. Third, invest in workforce training and credentialing programs for hospitals and specialty centers to ensure standardized delivery and post-therapy surveillance, thereby reducing variability in real-world outcomes.

Finally, pursue flexible commercial models that combine traditional pricing approaches with performance-linked arrangements and patient-support solutions. Build internal capabilities for health economics and outcomes research to quantify comparative value propositions and to inform payer negotiations. By implementing these measures, organizations will strengthen their clinical programs, secure more resilient supply chains, and create more credible value stories for diverse stakeholders.

Methodological transparency describing expert interviews, clinical and regulatory document synthesis, and triangulated evidence used to derive operationally relevant insights

The research approach combined qualitative and quantitative techniques to produce a rigorous analysis of clinical, operational, and policy dimensions. Primary research included structured interviews with clinical investigators, treatment center administrators, regulatory advisors, and payer representatives to capture real-world operational constraints and decision criteria. Secondary sources included peer-reviewed literature, clinicaltrials.gov listings, regulatory guidance documents, and industry white papers to contextualize clinical endpoints, safety signals, and regulatory precedents.

Data synthesis relied on triangulating insights from trial protocols, published safety and efficacy reports, and expert interviews to surface consistent themes and divergences. Supply-chain and tariff impact assessments were informed by customs documentation, logistics provider interviews, and manufacturer disclosures regarding sourcing strategies. The methodology also incorporated qualitative scenario mapping to explore plausible operational responses to regulatory shifts, payer engagement outcomes, and manufacturing contingencies.

To ensure reliability, findings were validated through follow-up discussions with select clinical and payer stakeholders and reviewed against the most recent regulatory guidelines. The resultant analysis emphasizes transparency about evidence sources and interpretive boundaries while offering practical recommendations grounded in observed practice and stakeholder priorities.

Concluding synthesis emphasizing the interplay of scientific progress, operational readiness, and multi-stakeholder evidence generation required for sustained therapeutic impact

Gene therapy for sickle cell disease is advancing into a stage where technical viability, clinical promise, and system-level readiness must coalesce to deliver meaningful patient benefit. Scientific innovation has lowered some historical technical barriers, but practical success will depend on coordinated investments in manufacturing resilience, clinician training, payer engagement, and long-term outcome capture. Stakeholders who proactively address these operational and evidentiary imperatives will find the most direct path to sustained clinical impact and responsible commercialization.

The field's trajectory suggests a shift from isolated clinical proof points to integrated programs that connect therapeutic platforms with delivery networks, payers, and patient communities. This shift requires transparent data-sharing agreements, pragmatic reimbursement dialogues, and iterative learning from early adoption pilots. Ultimately, the combination of robust clinical evidence, credible operational execution, and constructive payer partnerships will determine whether gene therapies for sickle cell disease deliver on their promise at scale.

As the ecosystem matures, continuous stakeholder alignment and adaptive strategies will remain essential. Organizations that marry scientific rigor with operational discipline and early payer-focused evidence generation will be best positioned to translate technological potential into durable patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gene Therapy for Sickle Cell Disease Market, by Treatment Model

  • 8.1. Allogeneic
  • 8.2. Autologous

9. Gene Therapy for Sickle Cell Disease Market, by Modification Technology

  • 9.1. Base Editing
  • 9.2. Cripr/Cas9
  • 9.3. Lentiviral Vector
  • 9.4. Zinc Finger Nuclease

10. Gene Therapy for Sickle Cell Disease Market, by Severity

  • 10.1. Moderate
  • 10.2. Severe

11. Gene Therapy for Sickle Cell Disease Market, by Payer Category

  • 11.1. Government
  • 11.2. Out Of Pocket
  • 11.3. Private

12. Gene Therapy for Sickle Cell Disease Market, by Patient Age

  • 12.1. Adult
  • 12.2. Pediatric

13. Gene Therapy for Sickle Cell Disease Market, by Distribution Channel

  • 13.1. Hospital
  • 13.2. Specialty Treatment Center

14. Gene Therapy for Sickle Cell Disease Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Gene Therapy for Sickle Cell Disease Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Gene Therapy for Sickle Cell Disease Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Gene Therapy for Sickle Cell Disease Market

18. China Gene Therapy for Sickle Cell Disease Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Agios Pharmaceuticals, Inc.
  • 19.6. Beam Therapeutics, Inc.
  • 19.7. Bluebird Bio, Inc.
  • 19.8. Bristol-Myers Squibb Company
  • 19.9. CRISPR Therapeutics AG
  • 19.10. Editas Medicine, Inc.
  • 19.11. EditForce, Inc.
  • 19.12. Emmaus Life Sciences, Inc.
  • 19.13. F. Hoffmann-La Roche Ltd.
  • 19.14. Fulcrum Therapeutics, Inc.
  • 19.15. Global Blood Therapeutics, Inc.
  • 19.16. Graphite Bio, Inc.
  • 19.17. Homology Medicines, Inc.
  • 19.18. Imara, Inc.
  • 19.19. Incyte Corporation
  • 19.20. Intellia Therapeutics, Inc.
  • 19.21. JCR Pharmaceuticals Co., Ltd.
  • 19.22. Magenta Therapeutics, Inc.
  • 19.23. Novartis AG
  • 19.24. Pfizer Inc.
  • 19.25. Precision BioSciences, Inc.
  • 19.26. Sangamo Therapeutics, Inc.
  • 19.27. Sanofi S.A.
  • 19.28. Vertex Pharmaceuticals Incorporated
  • 19.29. Vifor Pharma AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY BASE EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY BASE EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY BASE EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY CRIPR/CAS9, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY CRIPR/CAS9, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY CRIPR/CAS9, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY LENTIVIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY LENTIVIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY LENTIVIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY ZINC FINGER NUCLEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY ZINC FINGER NUCLEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY ZINC FINGER NUCLEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODERATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODERATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY GOVERNMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY GOVERNMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY GOVERNMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY OUT OF POCKET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY OUT OF POCKET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY OUT OF POCKET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PRIVATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SPECIALTY TREATMENT CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SPECIALTY TREATMENT CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SPECIALTY TREATMENT CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. GCC GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GCC GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 120. GCC GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. GCC GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 122. GCC GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 123. GCC GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 124. GCC GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. G7 GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. G7 GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 141. G7 GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. G7 GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 143. G7 GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 144. G7 GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 145. G7 GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. NATO GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. NATO GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 148. NATO GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. NATO GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 150. NATO GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 151. NATO GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 152. NATO GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY TREATMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY MODIFICATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PAYER CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA GENE THERAPY FOR SICKLE CELL DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)